This page is an English translation of the Korean original. If there is any discrepancy, the Korean version prevails.

Malignant Neoplasm of Uterus, Part Unspecified, C55자궁의 상세불명 부분의 악성신생물 (자궁암)

Special Copayment Reduction V193 — a copayment of 5% of covered medical care costs applies for 5 years from the date of cancer patient registration (the Cancer Control Act and the National Health Insurance special copayment reduction regulations)
Adult onset: very high | ICD-10: C55
Contents (Table of Contents)
  1. History
  2. Causes
  3. Genetics
  4. General epidemiology
  5. Pathophysiology
  6. Symptoms
  7. Signs
  8. Screening
  9. Diagnosis
  10. Treatment
  11. Prognosis
  12. Prevention
  13. References

1. History

ICD-10 code C55 (Malignant neoplasm of uterus, part unspecified) is a code covering malignant tumors of the uterus that cannot be clearly classified at diagnosis to a specific part of the uterus such as the cervix (C53) or corpus (C54). This code is used mainly for administrative and statistical purposes and is assigned when a specific site cannot be determined because of an insufficient biopsy specimen, autopsy findings, or incomplete diagnostic information.

The history of coding uterine malignancies parallels the development of the International Classification of Diseases (ICD). ICD-9 (1975) had a site-specific classification of the uterus, but it was less detailed than today. ICD-10 (1992) established a coding system that systematically divides uterine malignancies into C53 (cervix), C54 (corpus), C55 (unspecified) and C57 (other and unspecified female genital organs).

Clinical situations corresponding to C55 are mainly as follows: (1) tumors with extensive uterine involvement in which the cervix-corpus boundary cannot be clearly classified, (2) very rare malignant tumors of the uterus whose tissue of origin is unclear, (3) cases in which the site is unclear after the uterus was removed during the diagnostic process without review of the entire uterine pathology. Uterine sarcomas are classified to the corpus (C54.2 myometrium: leiomyosarcoma; C54.8: other), but may be coded as C55 when they involve the entire uterus or their origin is unclear.

In modern diagnostic systems, the number of cases classified as C55 is gradually decreasing owing to precise histologic classification, immunohistochemistry and molecular pathology testing. Nevertheless, the fact that the C55 code persists at a certain rate in cancer registry statistics reflects the limits of diagnostic information.

Understanding of uterine cancers has advanced dramatically in the fields of cervical cancer and endometrial cancer (see entries C53 and C54), and the C55 code, as their 'remainder category', has practical meaning in disease registration and insurance claim systems rather than in clinical practice.

The history of understanding uterine sarcoma is also noteworthy. Uterine leiomyosarcoma (LMS) has drawn clinicians' attention since the early 20th century because of the problem of distinguishing it from uterine fibroids. Endometrial stromal sarcoma (ESS) was classified into low grade and high grade by Norris and Taylor in 1966, and the 2014 WHO classification included a classification of uterine sarcomas based on molecular features such as JAZF1-SUZ12 rearrangement (low-grade ESS), YWHAE-NUTM2 rearrangement (high-grade ESS) and SMARCA4 deletion (undifferentiated uterine sarcoma).

2. Causes

The causes of unspecified malignant neoplasms of the uterus classified under code C55 encompass those of C53 (cervical cancer) and C54 (uterine corpus cancer). In actual clinical practice, tumors in C55 are often those involving the entire uterus or uterine sarcomas of unclear origin.

Causes related to cervical cancer (→ see entry C53)

High-risk HPV infection (types 16, 18, 31, 33, 45, 52, 58), smoking, immunosuppression, high parity and long-term oral contraceptive use are the main causes of cervical cancer. When the tumor extensively involves the corpus from the cervix so that the site cannot be classified, it is coded as C55.

Causes related to uterine corpus cancer (→ see entry C54)

Obesity, estrogen-only hormone therapy, PCOS, diabetes, tamoxifen use and nulliparity are the main causes of estrogen-dependent endometrial cancer. Lynch syndrome (germline mutations of MLH1, MSH2, MSH6, PMS2) is the most important cause of hereditary endometrial cancer.

Specific causes of uterine sarcoma

3. Genetics

The genetics of unspecified malignant neoplasms of the uterus classified as C55 vary according to the actual histologic origin of the tumor.

Genomic features of uterine sarcoma

Uterine leiomyosarcoma (LMS) is characterized by TP53 mutation (~40–60%), RB1 deletion, ATRX mutation and PTEN mutation. It shows complex chromosomal abnormalities (complex karyotype), and MDM2 amplification is rare (differentiation from liposarcoma needed). Low-grade endometrial stromal sarcoma (LG-ESS) is most characterized by the JAZF1 (7p15.2)-SUZ12 (17q11.2) reciprocal translocation t(7;17)(p15;q11), found in about 70%. SUZ12 is a component of PRC2 (polycomb repressive complex 2), and JAZF1-SUZ12 fusion causes abnormalities in H3K27 methylation and regulation of gene expression. High-grade endometrial stromal sarcoma (HG-ESS) is characterized by the YWHAE (17p13.3)-NUTM2 (10q22) translocation, which is used as a biomarker to distinguish it from LG-ESS. Undifferentiated uterine sarcoma (UUS) has reported SMARCA4 (SWI/SNF complex) deletion or mutation and has a very poor prognosis.

Genomic features of carcinosarcoma

Carcinosarcoma is a biphasic tumor with mixed epithelial (carcinoma) and mesenchymal (sarcoma) components. Clonal analysis has shown that the two components share the same genetic origin, so it is now understood as endometrial carcinoma that has undergone sarcomatous dedifferentiation. TP53 mutation (about 55–60%), PIK3CA mutation and FBXW7 mutation are shared by both components. HER2 overexpression/amplification is observed in about 16–18% of the carcinoma component, and the potential of trastuzumab-based treatment is being studied.

Genetics of cancer with extensive uterine involvement

When a tumor extensively involves the corpus from the cervix and is classified as C55, its genetic features follow the primary site (cervical cancer vs. endometrial cancer). HPV positivity strongly suggests a cervical origin, and PIK3CA mutation, TP53 mutation (HPV-negative cervical or endometrial p53abn subtype) and others are used as adjuncts to determine the site.

4. General epidemiology

Epidemiologic data for the C55 code itself are limited, and most epidemiologic studies concern uterine cancers classified as C53 and C54. C55 is an unclassified code in cancer registry data and accounts for a portion of all uterine malignancies.

Epidemiology of uterine sarcoma

Uterine sarcoma is a rare tumor accounting for about 3–9% of all uterine malignancies. About 6,000 people are diagnosed with uterine sarcoma annually in the United States. Uterine leiomyosarcoma (LMS) accounts for about 60–70% of uterine sarcomas, endometrial stromal sarcoma (ESS) about 10–15%, carcinosarcoma about 15–20%, and other undifferentiated sarcomas make up the rest. The median age at diagnosis is about the 50s for LMS (around menopause) and the 40s–50s for ESS. The overall 5-year survival rate of uterine sarcoma is 40–50% (varying greatly with stage and histologic type).

Epidemiology of carcinosarcoma

Carcinosarcoma occurs predominantly in elderly (median age 65–68) postmenopausal women and has a relatively higher incidence in Black women. Prior pelvic radiotherapy is an important risk factor.

Type of uterine sarcomaProportionMedian age5-year survival
Leiomyosarcoma (LMS)~60~70%50s40–55% (stage-dependent)
Low-grade endometrial stromal sarcoma (LG-ESS)~10~15%40s–50s75–90% (stage I)
High-grade endometrial stromal sarcoma (HG-ESS)~5~10%50s25~50%
Carcinosarcoma~15~20%65–68 years20~40%
Undifferentiated uterine sarcoma (UUS)<5%60s10~25%

5. Pathophysiology

Pathophysiology of uterine leiomyosarcoma (LMS)

The pathophysiology of uterine LMS has not been fully elucidated. Most LMS are understood to arise de novo from normal myometrial smooth muscle cells or perivascular smooth muscle cells. Malignant transformation from a uterine fibroid (leiomyoma) is possible but is estimated to be very rare (less than 0.1–0.3%). Loss of TP53 function is an early key event, and a p53-negative/overexpression pattern is observed on IHC. When RB1 deletion and TP53 mutation occur together, the two key systems of cell cycle control collapse simultaneously, causing rapid malignant proliferation. The alternative lengthening of telomeres (ALT) mechanism due to ATRX (DAXX/ATRX complex) mutation contributes to genomic instability in LMS.

Pathophysiology of low-grade endometrial stromal sarcoma (LG-ESS)

Formation of the JAZF1-SUZ12 fusion gene is central. SUZ12 is an essential component of PRC2 (Polycomb Repressive Complex 2), which represses developmental gene expression through H3K27 trimethylation (H3K27me3). The JAZF1-SUZ12 fusion protein reduces the histone methyltransferase activity of PRC2, causing failure of differentiation control, and is also involved in promoting cell proliferation through estrogen-progestin signaling. LG-ESS strongly expresses estrogen receptor (ER) and progestin receptor (PR), showing hormone-dependent growth that responds to aromatase inhibitors or progestin therapy.

Pathophysiology of carcinosarcoma

The currently prevailing theory is that carcinosarcoma starts from an endometrial carcinoma of monoclonal origin, and the sarcoma component develops through epithelial-mesenchymal transition (EMT). TP53, FBXW7, KRAS and PTEN mutations are shared by both components, and these shared mutations support origin from a common ancestral cell. Highly complex chromosomal abnormalities and overall genomic instability are characteristic.

6. Symptoms

Symptoms of unspecified malignant neoplasms of the uterus classified as C55 (extensive cervix-corpus involvement, uterine sarcoma, etc.) vary with the location and histologic type of the lesion.

Main symptoms

Symptoms of endometrial stromal sarcoma (ESS)

Abnormal uterine bleeding, pelvic pain and uterine enlargement are the main symptoms. LG-ESS progresses slowly, and in some cases only mild symptoms are present for a long time, delaying diagnosis.

7. Signs

Physical examination findings

Specific signs of uterine sarcoma

8. Screening

No specific screening test exists for the uterine malignant neoplasms corresponding to C55. Uterine sarcoma is rarely diagnosed by screening before symptoms appear.

Detection of tumors with extensive cervix-corpus involvement

During cervical cancer screening (cervical cytology, HPV testing), an advanced tumor extending from the cervix to the corpus may be found. Endometrial cancer evaluation (endometrial assessment for abnormal bleeding) may find a tumor extensively involving the cervix from the uterine corpus.

Limitations of screening for uterine sarcoma

Surveillance of high-risk groups

9. Diagnosis

Imaging

Histological diagnosis

Immunohistochemistry and molecular testing

When the site cannot be classified (C55)

When extensive uterine involvement prevents clear distinction between the cervix and corpus, or when preoperative tissue diagnosis confirms uterine origin but the specific site is unclear, the case is provisionally coded as C55 and reclassified according to the final postoperative pathology.

10. Treatment

Surgical treatment of uterine sarcoma

The basic surgery for uterine sarcoma is total hysterectomy + bilateral salpingo-oophorectomy. Complete removal of LMS by myomectomy alone is insufficient, and use of a power morcellator is contraindicated because of the risk of intraperitoneal dissemination of LMS (2014 FDA safety warning). Indications for lymph node dissection differ by histologic type; in LMS the lymph node metastasis rate is low, so routine lymph node dissection is sometimes not recommended. In ESS, resection of the ligaments (wide resection) is important for preventing recurrence.

Adjuvant treatment of uterine sarcoma

Tumors with extensive uterine involvement (unclear cervix-corpus boundary)

When operable, radical hysterectomy is performed, and adjuvant treatment following C53 or C54 is applied according to the tissue of origin confirmed after surgery. In inoperable advanced stages, radiotherapy (CCRT) or systemic chemotherapy is given.

Treatment of recurrent uterine sarcoma

11. Prognosis

5-year survival of uterine sarcoma by stage

Histologic typeStage I 5-year OSStage II–III 5-year OSStage IV 5-year OS
Leiomyosarcoma (LMS)50~65%25~40%5~15%
Low-grade ESS (LG-ESS)75~90%50~70%25~40%
High-grade ESS (HG-ESS)40~55%15~30%<10%
Carcinosarcoma40~55%15~25%5~15%
Undifferentiated uterine sarcoma (UUS)20~35%5~15%<5%

Prognostic factors

12. Prevention

Prevention of uterine sarcoma

There is currently no primary prevention for uterine leiomyosarcoma. Because the rate of malignant transformation from a uterine fibroid (leiomyoma) to LMS is very low, prophylactic surgery for all patients with fibroids is not recommended. However, rapid growth of a fibroid or development of new fibroids after menopause requires evaluation to exclude LMS.

Restricting power morcellator use

In 2014, the US FDA issued a safety warning on the use of power morcellators during myomectomy or hysterectomy for unconfirmed uterine masses. Morcellator use is prohibited when LMS is suspected or has not been excluded. Equivalent guidance applies in Korea as well.

Prevention of tumors with extensive uterine involvement (→ see entries C53, C54)

Early detection of cervical cancer through HPV vaccination and screening, and weight management and minimizing estrogen exposure for endometrial cancer, can indirectly prevent tumors with extensive uterine involvement (advanced tumors that may be classified as C55).

Prophylactic surgery in women with Lynch syndrome

Performing prophylactic hysterectomy + bilateral salpingo-oophorectomy after completion of childbearing can greatly lower the risk of endometrial and ovarian cancer.

13. References

  1. WHO Classification of Tumours of Female Genital Tract, 5th ed. 2020. IARC, Lyon.
  2. Mbatani N, et al. Uterine sarcomas. Best Pract Res Clin Obstet Gynaecol. 2015;29(6):786-797.
  3. ESMO Guidelines: Uterine Sarcomas. Ann Oncol. 2018;29(Suppl 4):iv51-iv58.
  4. FDA Safety Communication: Laparoscopic Uterine Power Morcellation. 2014.
  5. Hensley ML, et al. Gemcitabine and Docetaxel in Patients with Unresectable Leiomyosarcoma. J Clin Oncol. 2002;20(12):2824-2831.
  6. Reed NS, et al. Phase III Randomized Study to Evaluate the Role of Adjuvant Pelvic Radiotherapy in Uterine Sarcoma. Eur J Cancer. 2008;44(6):808-818.
  7. ICD-10 Clinical Modification. WHO. C55 Malignant neoplasm of uterus, part unspecified. 1992.
  8. Norris HJ, Taylor HB. Mesenchymal Tumors of the Uterus. Cancer. 1966;19(6):755-766.
  9. Korean Society of Gynecologic Oncology. Guidelines for Gynecologic Cancers. 2023.
  10. Pautier P, et al. Trabectedin in Advanced Uterine Leiomyosarcomas. Ann Oncol. 2016;27(1):166-171.